Safety of Intrauterine Transfusion Performed Beyond 34 weeks of Gestation.
Journal
Prenatal diagnosis
ISSN: 1097-0223
Titre abrégé: Prenat Diagn
Pays: England
ID NLM: 8106540
Informations de publication
Date de publication:
20 Sep 2024
20 Sep 2024
Historique:
revised:
11
07
2024
received:
19
04
2024
accepted:
04
09
2024
medline:
21
9
2024
pubmed:
21
9
2024
entrez:
21
9
2024
Statut:
aheadofprint
Résumé
To describe (1) procedure-related complications, and (2) gestational age (GA) at delivery in patients who received their final intrauterine transfusion (IUT) at ≥ 34 weeks 0 days versus at < 34 weeks 0 days. This was a retrospective study of pregnancies treated with IUT. Procedure-related complications were defined as any of the following within 48 h of IUT: (1) rupture of membranes or preterm delivery, (2) intrauterine infection, (3) fetal death, (4) fetal compromise resulting in emergency cesarean, or (5) neonatal death. Patient and procedural characteristics were described among patients with final IUT at ≥ 34 weeks 0 days and at < 34 weeks 0 days. We studied 94 pregnancies with 237 IUTs; 35 (37.2%) had their last IUT at ≥ 34 weeks 0 days and 59 (62.8%) had their last IUT at < 34 weeks 0 days. Three procedure-related complications occurred (1.3% of procedures, 3.2% of pregnancies). All resulted in emergency cesarean section; 1 case performed at < 34 weeks 0 days resulted in neonatal death. The remaining 2 occurred during IUT at ≥ 34 weeks 0 days. Pregnancies with the last IUT at ≥ 34 weeks 0 days delivered at a median GA of 37.1 weeks. Complications were rare. IUT performed at ≥ 34 weeks 0 days appeared safe.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
J. S. Castleman and M. D. Kilby, “Red Cell Alloimmunization: A 2020 Update,” Prenatal Diagnosis 40, no. 9 (2020): 1099–1108, https://doi.org/10.1002/pd.5674.
“ACOG Practice Bulletin No. 192: Management of Alloimmunization During Pregnancy,” Obstetrics & Gynecology 131, no. 3 (2018): e82–e90, https://doi.org/10.1097/AOG.0000000000002528.
“Practice Bulletin No. 181: Prevention of Rh D Alloimmunization,” Obstetrics & Gynecology 130, no. 2 (2017): e57–e70, https://doi.org/10.1097/AOG.0000000000002232.
G. Mari, G. Mari, M. E. Norton, et al., “Society for Maternal‐Fetal Medicine (SMFM) Clinical Guideline #8: The Fetus at Risk for Anemia—Diagnosis and Management,” American Journal of Obstetrics and Gynecology 212, no. 6 (2015): 697–710, https://doi.org/10.1016/j.ajog.2015.01.059.
C. Zwiers, I. T. M. Lindenburg, F. J. Klumper, M. de Haas, D. Oepkes, and I. L. Van Kamp, “Complications of Intrauterine Intravascular Blood Transfusion: Lessons Learned After 1678 Procedures,” Ultrasound in Obstetrics and Gynecology 50, no. 2 (2017): 180–186, https://doi.org/10.1002/uog.17319.
V. Urutherakumar, A. Welsh, and A. Henry, “Short‐Term Outcomes Following Intrauterine Transfusions for Fetal Anaemia: A Retrospective Cohort Study,” Australian and New Zealand Journal of Obstetrics and Gynaecology 60, no. 5 (2020): 738–745, https://doi.org/10.1111/ajo.13155.
E. Tiblad, M. Kublickas, G. Ajne, et al., “Procedure‐Related Complications and Perinatal Outcome After Intrauterine Transfusions in Red Cell Alloimmunization in Stockholm,” Fetal Diagnosis and Therapy 30, no. 4 (2011): 266–273, https://doi.org/10.1159/000328683.
S. Sainio, I. Nupponen, M. Kuosmanen, et al., “Diagnosis and Treatment of Severe Hemolytic Disease of the Fetus and Newborn: A 10‐year Nationwide Retrospective Study,” Acta Obstetricia et Gynecologica Scandinavica 94, no. 4 (2015): 383–390, https://doi.org/10.1111/aogs.12590.
U. Blyth, M. Larsson, A. Baird, G. Waring, and N. Athiraman, “Neonatal Outcomes Following Intrauterine Transfusion for Hemolytic Disease of the Fetus and Newborn: A Twenty‐Year Service Review,” Journal of Maternal‐Fetal and Neonatal Medicine 35, no. 25 (2022): 1–6, https://doi.org/10.1080/14767058.2022.2122041.
C. Johnstone‐Ayliffe, T. Prior, C. Ong, F. Regan, and S. Kumar, “Early Procedure‐Related Complications of Fetal Blood Sampling and Intrauterine Transfusion for Fetal Anemia,” Acta Obstetricia et Gynecologica Scandinavica 91, no. 4 (2012): 458–462, https://doi.org/10.1111/j.1600‐0412.2011.01353.x.
C. Zwiers, I. van Kamp, D. Oepkes, and E. Lopriore, “Intrauterine Transfusion and Non‐Invasive Treatment Options for Hemolytic Disease of the Fetus and Newborn—Review on Current Management and Outcome,” Expert Review of Hematology 10, no. 4 (2017): 337–344, https://doi.org/10.1080/17474086.2017.1305265.
A. O. Savkli, B. A. Cetin, Z. Acar, et al., “Perinatal Outcomes of Intrauterine Transfusion for Foetal Anaemia Due to Red Blood Cell Alloimmunisation,” Journal of Obstetrics and Gynaecology (Abingdon) 40, no. 5 (2020): 649–653, https://doi.org/10.1080/01443615.2019.1647521.
S. Bakhtary, T. Panchalee, E. P. Crowe, et al., “Survey of Intrauterine Red Blood Cell (RBC) Transfusion Practices in the United States,” Transfusion 62, no. 12 (2022): 2449–2453, https://doi.org/10.1111/trf.17134.
R. Donepudi, E. Antolin, F. Molina, et al., “Practice Patterns Amongst Fetal Centers Performing Intrauterine Transfusions (PACT): An International Survey Study,” European Journal of Obstetrics & Gynecology and Reproductive Biology 274 (2022): 171–174, https://doi.org/10.1016/j.ejogrb.2022.05.027.
The Management of Women With Red Cell Antibodies During Pregnancy. (London: Royal College of Obstetricians and Gynaecologists, 2014).
The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. “Statements and Guidelines Directory,” http://ranzcog.edu.au/resources/statements‐and‐guidelines‐directory/.
H. V. New, S. J. Stanworth, R. Gottstein, et al., “British Society for Haematology Guidelines on Transfusion for Fetuses, Neonates and Older Children (Br J Haematol. 2016; 175: 784–828). Addendum August 2020,” British Journal of Haematology 191, no. 5 (2020): 725–727, https://doi.org/10.1111/bjh.17109.
B. H. Grubbs, L. M. Korst, A. Llanes, and R. H. Chmait, “Middle Cerebral Artery Doppler and Hemoglobin Changes Immediately Following Fetal Transfusion,” Journal of Maternal‐Fetal and Neonatal Medicine 26, no. 2 (2013): 155–157, https://doi.org/10.3109/14767058.2012.725114.
E. Arslan, S. C. Demir, M. Ozsurmeli, and C. Akcabay, “Perinatal Outcomes and Survival Predictors of Severe Red‐Cell Alloimmunization Treated by Intrauterine Transfusion,” Journal of Obstetrics and Gynaecology Research 47, no. 8 (2021): 2632–2640, https://doi.org/10.1111/jog.14860.
A. Alkhaibary, M. Ali, M. Tulbah, et al., “Complications of Intravascular Intrauterine Transfusion for Rh Alloimmunization,” Annals of Saudi Medicine 41, no. 6 (2021): 313–317, https://doi.org/10.5144/0256‐4947.2021.313.
U. Blyth, M. Larsson, A. Baird, G. Waring, and N. Athiraman, “Neonatal Outcomes Following Intrauterine Transfusion for Hemolytic Disease of the Fetus and Newborn: A Twenty‐Year Service Review,” Journal of Maternal‐Fetal and Neonatal Medicine 35, no. 25 (2022): 10220–10225, https://doi.org/10.1080/14767058.2022.2122041.
D. Deka, V. Dadhwal, A. K. Sharma, et al., “Perinatal Survival and Procedure‐Related Complications After Intrauterine Transfusion for Red Cell Alloimmunization,” Archives of Gynecology and Obstetrics 293, no. 5 (2016): 967–973, https://doi.org/10.1007/s00404‐015‐3915‐7.
S. Liu, G. Ajne, A. Wikman, C. Lindqvist, M. Reilly, and E. Tiblad, “Management and Clinical Consequences of Red Blood Cell Antibodies in Pregnancy: A Population‐Based Cohort Study,” Acta Obstetricia et Gynecologica Scandinavica 100, no. 12 (2021): 2216–2225, https://doi.org/10.1111/aogs.14261.
F. J. Klumper, I. L. van Kamp, F. P. Vandenbussche, et al., “Benefits and Risks of Fetal Red‐Cell Transfusion After 32 Weeks Gestation,” European Journal of Obstetrics & Gynecology and Reproductive Biology 92, no. 1 (2000): 91–96, https://doi.org/10.1016/s0301‐2115(00)00430‐9.
S. A. Pasman, L. Claes, L. Lewi, et al., “Intrauterine Transfusion for Fetal Anemia Due to Red Blood Cell Alloimmunization: 14 Years Experience in Leuven,” Facts, Views and Vision ObGyn 7, no. 2 (2015): 129–136, https://www.ncbi.nlm.nih.gov/pubmed/26175890.
R. V. Donepudi, A. Javinani, S. Mostafaei, et al., “Perinatal Survival Following Intrauterine Transfusion for Red Cell Alloimmunized Pregnancies: Systematic Review and Meta‐Regression,” American Journal of Obstetrics and Gynecology 230, no. 3 (2023): e1–e2, https://doi.org/10.1016/j.ajog.2023.10.016.
I. T. Lindenburg, R. Wolterbeek, D. Oepkes, F. J. Klumper, F. P. Vandenbussche, and I. L. van Kamp, “Quality Control for Intravascular Intrauterine Transfusion Using Cumulative Sum (CUSUM) Analysis for the Monitoring of Individual Performance,” Fetal Diagnosis and Therapy 29, no. 4 (2011): 307–314, https://doi.org/10.1159/000322919.
R. N. Spencer, K. Hecher, G. Norman, et al., “Development of Standard Definitions and Grading for Maternal and Fetal Adverse Event Terminology,” Prenatal Diagnosis 42, no. 1 (2022): 15–26, https://doi.org/10.1002/pd.6047.
S. Vergote, J. Van der Stock, Y. Kunpalin, et al., “Patient Empowerment Improves Follow‐Up Data Collection After Fetal Surgery for Spina Bifida: Institutional Audit,” Ultrasound in Obstetrics and Gynecology 62, no. 4 (2023): 565–572, https://doi.org/10.1002/uog.26230.